{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:11Z","timestamp":1787020691483,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02916-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:30:44Z","timestamp":1761568244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["What leads to treatment failure among people living with HIV: first systematic review from the middle east and North Africa"],"prefix":"10.1186","volume":"22","author":[{"given":"Farima","family":"Safari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Hashempour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Khodadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad matin Karbalaee","family":"Alinazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokufeh","family":"Akbarinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amirhossein","family":"Tabatabaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2916_CR1","unstructured":"Khalilian A, Karami P, Bakhtyari S, Ezati R, Khosravi S, Amini R et al. Prevalence of Helicobacter felis and Helicobacter heilmannii and Co-infection With Helicobacter pylori in Gastric Biopsy Specimens in Endoscopy Ward of Shahid Beheshti Hospital, Hamadan City, Iran. 2022."},{"key":"2916_CR2","doi-asserted-by":"crossref","unstructured":"Zomorodi AR, Mohommadi M, Farshi ZG, Mashhadi MHP, Benam SP, Motamedifar MJTOS. Prevalence and antimicrobial susceptibility pattern of coagulase-negative Staphylococci isolated from ocular infections: a systematic review and meta-analysis. 2025.","DOI":"10.1016\/j.jtos.2025.03.006"},{"issue":"3","key":"2916_CR3","first-page":"e70164","volume":"13","author":"M Nejabat","year":"2025","unstructured":"Nejabat M, Motamedifar M, Fard SA, Heydari M, Bemani SJI. Inflammation, disease. Immune dysregulation in HIV and COVID-19 Co\u2010infection. Therapeutic Implications. 2025;13(3):e70164.","journal-title":"Therapeutic Implications"},{"key":"2916_CR4","doi-asserted-by":"crossref","unstructured":"Khodadad N, Seyedian SS, Haghighi SB, Makvandi MJFV. Molecular characterization and phylogenetic analyses of full-length viral genomes from Iranian patients with chronic hepatitis B virus. 2021;16(10):667\u201375.","DOI":"10.2217\/fvl-2020-0422"},{"key":"2916_CR5","doi-asserted-by":"crossref","unstructured":"Moshaverinia M, Najarkarimi F, Karimzadeh D, Lavaee F, Zarshenas MM, Motamedifar MJSE-MJ. Comparison of the antibacterial effect of the essence and hydroalcoholic extract of celery (Apium graveolens) against Streptococcus mutans in vitro. 2025;26(4).","DOI":"10.5812\/semj-157299"},{"key":"2916_CR6","doi-asserted-by":"crossref","unstructured":"Zomorodi AR, Motamedifar M, Rahmanian K, Shakeri M, Hajikhani B, Heidari H et al. Investigation of integron classes 1, 2, and 3 among multi-drug resistant Staphylococcus aureus isolates in iran: a multi-center study. 2024;24(1):1430.","DOI":"10.1186\/s12879-024-10311-5"},{"key":"2916_CR7","doi-asserted-by":"crossref","unstructured":"Farshchi Tabrizi A, Rafati Zomorodi A, Kakian F, Moazemy A, Kasraian L, Nakhaeitazeji S et al. Prevalence of Chlorhexidine-Tolerant Pseudomonas aeruginosa and correlation with antibiotic resistance. 2024;18(4):214\u201322.","DOI":"10.30699\/ijmm.18.4.214"},{"key":"2916_CR8","doi-asserted-by":"crossref","unstructured":"Heydari M, Foroozanfar Z, Bazmi S, Mohammadi Z, Joulaei H, Ansari GJBID. The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance. 2024;24(1):1123.","DOI":"10.1186\/s12879-024-09958-x"},{"key":"2916_CR9","unstructured":"HIV UG. AIDS statistics\u20132022 fact sheet. Accessed April. 2023;26."},{"key":"2916_CR10","unstructured":"DRuGS A. tHe uSe of ANtIRetRoVIRAL DRuGS foR tReAtING AND PReVeNtING HIV INfeCtIoN. 2013."},{"issue":"1","key":"2916_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/01.qai.0000248351.10383.b7","volume":"44","author":"GK Robbins","year":"2007","unstructured":"Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. JAIDS J Acquir Immune Defic Syndr. 2007;44(1):30\u20137.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"6","key":"2916_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/COH.0b013e328331dea5","volume":"4","author":"JL Aldous","year":"2009","unstructured":"Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4(6):459\u201366.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"2916_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/QAD.0b013e3282f2be1d","volume":"22","author":"EG Chadwick","year":"2008","unstructured":"Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, et al. Pharmacokinetics, safety and efficacy of lopinavir\/ritonavir in infants less than 6 months of age: 24 week results. Aids. 2008;22(2):249\u201355.","journal-title":"Aids"},{"issue":"3","key":"2916_CR14","first-page":"404","volume":"70","author":"Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children","year":"2020","unstructured":"Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children. Adolescents with human immunodeficiency virus in Europe and thailand: cohort study. Clinical infectious diseases: an official publication of the infectious diseases. Soc Am. 2020;70(3):404\u201315.","journal-title":"Soc Am"},{"issue":"9","key":"2916_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/QAD.0b013e32832afefc","volume":"23","author":"K Smith","year":"2009","unstructured":"Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. Aids. 2009;23(9):1097\u2013107.","journal-title":"Aids"},{"issue":"1","key":"2916_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12879-024-09251-x","volume":"24","author":"A Hashempour","year":"2024","unstructured":"Hashempour A, Khodadad N, Ziaei R, Rezaei B, Ghasabi F, Falahi S, et al. Predictors of antiretroviral treatment failure to the first line therapy: a cross-sectional study among Iranian HIV-positive adults. BMC Infect Dis. 2024;24(1):358.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2916_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/COH.0b013e328331dea5","volume":"4","author":"J Aldous","year":"2009","unstructured":"Aldous J, Haubrich R. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4(6):459\u201366.","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"2916_CR18","doi-asserted-by":"publisher","first-page":"e1001907","DOI":"10.1371\/journal.pmed.1001907","volume":"12","author":"A Dutta","year":"2015","unstructured":"Dutta A, Barker C, Kallarakal A. The HIV treatment gap: estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020. PLoS Med. 2015;12(11):e1001907.","journal-title":"PLoS Med"},{"key":"2916_CR19","unstructured":"REDUCTIONS. P. ANTIRETROVIRAL."},{"key":"2916_CR20","doi-asserted-by":"crossref","unstructured":"Getawa S, Fentahun A, Adane T, Melku M. Antiretroviral treatment failure and associated factors among HIV-infected children on antiretroviral therapy: a retrospective study. HIV\/AIDS-Research and Palliative Care. 2021:229\u2009\u2013\u200937.","DOI":"10.2147\/HIV.S294046"},{"key":"2916_CR21","volume-title":"HIV and AIDS in the middle East and North Africa","author":"H Setayesh","year":"2014","unstructured":"Setayesh H, Roudi-Fahimi F, El Feki S, Ashford LS. HIV and AIDS in the middle East and North Africa. Washington, DC: Population Reference Bureau; 2014."},{"key":"2916_CR22","unstructured":"Akala FA, Semini I. Characterizing the HIV\/AIDS epidemic in the middle East and North africa: time for strategic action. World Bank; 2010."},{"issue":"5","key":"2916_CR23","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/ijerph20053844","volume":"20","author":"A Karbasi","year":"2023","unstructured":"Karbasi A, Fordjuoh J, Abbas M, Iloegbu C, Patena J, Adenikinju D, et al. An evolving HIV epidemic in the middle East and North Africa (MENA) region: A scoping review. Int J Environ Res Public Health. 2023;20(5):3844.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"2916_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17441692.2019.1668452","volume":"15","author":"GR Mumtaz","year":"2020","unstructured":"Mumtaz GR, Hilmi N, Majed EZ, Abu-Raddad LJ. Characterising HIV\/AIDS knowledge and attitudes in the middle East and North africa: systematic review and data synthesis. Glob Public Health. 2020;15(2):275\u201398.","journal-title":"Glob Public Health"},{"key":"2916_CR25","doi-asserted-by":"crossref","unstructured":"Moradi A, Alammehrjerdi Z, Daneshmand R, Amini-Lari M, Zarghami M, Dolan K. HIV responses in Arab States on the Southern Persian Gulf border: the first review. Iran J Psychiatry Behav Sci. 2016;10(3).","DOI":"10.17795\/ijpbs-5392"},{"issue":"7","key":"2916_CR26","first-page":"e25967","volume":"25","author":"MC DiCarlo","year":"2022","unstructured":"DiCarlo MC, Dallabetta GA, Akolo C, Bautista-Arredondo S, Digolo HV, Fonner VA, et al. Adequate funding of comprehensive community\u2010based programs for key populations needed now more than ever to reach and sustain HIV targets. Afr J Reprod Gynaecol Endoscopy. 2022;25(7):e25967.","journal-title":"Afr J Reprod Gynaecol Endoscopy"},{"key":"2916_CR27","doi-asserted-by":"crossref","unstructured":"Kianmehr S, Vahabirad M, Seghatoleslam A, Sadeghi E, Kiani R, Ghasemi HJUR et al. Prognostic value of TGF-\u03b2 expression in bladder cancer: A systematic review and Meta-analysis. 2024;50(3):148.","DOI":"10.5152\/tud.2024.24024"},{"key":"2916_CR28","doi-asserted-by":"crossref","unstructured":"Zamani M, Sadeghi E, Mokarram P, Kadkhodaei B, Ghasemi HJIJRB. Autophagy related proteins as potential biomarkers in predicting cancer prognosis after chemoradiotherapy: systematic review and meta-analysis. 2025;101(3):232\u20139.","DOI":"10.1080\/09553002.2024.2435320"},{"issue":"3","key":"2916_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/0956462420956850","volume":"32","author":"A Elgalib","year":"2021","unstructured":"Elgalib A, Al-Wahaibi A, Shah S, Al-Habsi Z, Al-Fouri M, Lau R, et al. Predictors of virologic failure among people living with HIV in oman: a National study from the middle East. Int J STD AIDS. 2021;32(3):239\u201345.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"2916_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5001\/omj.2018.55","volume":"33","author":"F Khamis","year":"2018","unstructured":"Khamis F, Al Noamani J, Al Naamani H, Al-Zakwani I. Epidemiological and clinical characteristics of HIV infected patients at a tertiary care hospital in Oman. Oman Med J. 2018;33(4):291\u20138.","journal-title":"Oman Med J"},{"key":"2916_CR31","doi-asserted-by":"publisher","first-page":"232595822097981","DOI":"10.1177\/2325958220979817","volume":"19","author":"Z Gaifer","year":"2020","unstructured":"Gaifer Z, Boulassel M-R. Low-level viremia predicts virological failure in HIV-infected Omani patients receiving antiretroviral therapy. J Int Association Providers AIDS Care (JIAPAC). 2020;19:2325958220979817.","journal-title":"J Int Association Providers AIDS Care (JIAPAC)"},{"key":"2916_CR32","doi-asserted-by":"crossref","unstructured":"Januszka J, Drwiega E, Burgos R, Smith R, Badowski M. Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy. Drugs Context. 2024;13.","DOI":"10.7573\/dic.2023-12-4"},{"issue":"9","key":"2916_CR33","doi-asserted-by":"publisher","first-page":"ofaa316","DOI":"10.1093\/ofid\/ofaa316","volume":"7","author":"SY Rhee","year":"2020","unstructured":"Rhee SY, Clutter D, Hare CB, Tchakoute CT, Sainani K, Fessel WJ, et al. Virological failure and acquired genotypic resistance associated with contemporary antiretroviral treatment regimens. Open Forum Infect Dis. 2020;7(9):ofaa316.","journal-title":"Open Forum Infect Dis"},{"key":"2916_CR34","unstructured":"Pengtao Liu P, Lingjie Liao, PhDb W, Xu MD, MDb JY, Zuo Z, MDb X, Leng MD, Wang J, MDb W, Kan YR. PhDb,c,\u2217, Yiming Shao, MD, PhDb,c. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015. Medicine (Baltimore). 2018."},{"issue":"10","key":"2916_CR35","doi-asserted-by":"publisher","first-page":"e005886","DOI":"10.1136\/bmjopen-2014-005886","volume":"4","author":"X Leng","year":"2014","unstructured":"Leng X, Liang S, Ma Y, Dong Y, Kan W, Goan D, et al. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China. BMJ Open. 2014;4(10):e005886.","journal-title":"BMJ Open"},{"key":"2916_CR36","doi-asserted-by":"crossref","unstructured":"Shafiq M, Zafar S, Ahmad A, Kazmi A, Fatima A, Mujahid TA et al. Second-Line antiretroviral treatment outcome in HIV\u2010Infected patients coinfected with tuberculosis in Pakistan. 2023;2023(1):4187488.","DOI":"10.1155\/2023\/4187488"},{"key":"2916_CR37","doi-asserted-by":"crossref","unstructured":"Rasoolinejad M, Sarraf M, Najafi Z, SeyedAlinaghi S, Badie BM, Salehi M et al. Virologic failure in different antiretroviral regimens among pediatric patients with HIV referring to a voluntary counseling and testing (VCT) center in tehran, Iran (2004\u20132017). Archives Pediatr Infect Dis. 2019;7(4).","DOI":"10.5812\/pedinfect.80318"},{"issue":"2","key":"2916_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0253-7184.85412","volume":"32","author":"B Prabhakar","year":"2011","unstructured":"Prabhakar B, Banu A, Pavithra H, Chandrashekhara P, Sasthri S. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian J Sexually Transmitted Dis AIDS. 2011;32(2):94\u20138.","journal-title":"Indian J Sexually Transmitted Dis AIDS"},{"issue":"2","key":"2916_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jac\/dkab406","volume":"77","author":"S Henerico","year":"2022","unstructured":"Henerico S, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S, Lyimo E, et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. J Antimicrob Chemother. 2022;77(2):483\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2916_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5001\/omj.2018.55","volume":"33","author":"F Khamis","year":"2018","unstructured":"Khamis F, Al Noamani J, Al Naamani H, Al-Zakwani I. Epidemiological and clinical characteristics of HIV infected patients at a tertiary care hospital in Oman. Oman Med J. 2018;33(4):291.","journal-title":"Oman Med J"},{"issue":"1","key":"2916_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09540121.2021.1991880","volume":"35","author":"A Elgalib","year":"2023","unstructured":"Elgalib A, Shah S, Al-Wahaibi A, Al-Habsi Z, Al-Fouri M, Lau R, et al. Treatment outcomes 12 months after antiretroviral therapy initiation in oman: a nationwide study from the middle East. AIDS Care. 2023;35(1):63\u201370.","journal-title":"AIDS Care"},{"issue":"11","key":"2916_CR42","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1089\/aid.2004.20.1166","volume":"20","author":"SH Al Dhahry","year":"2004","unstructured":"Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, et al. Human immunodeficiency virus type 1 infection in oman: antiretroviral therapy and frequencies of drug resistance mutations. AIDS Res Hum Retroviruses. 2004;20(11):1166\u201372.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"2916_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12981-020-00294-z","volume":"17","author":"J Nega","year":"2020","unstructured":"Nega J, Taye S, Million Y, Rodrigo C, Eshetie S. Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in sekota, Northeast Ethiopia. AIDS Res Therapy. 2020;17(1):39.","journal-title":"AIDS Res Therapy"},{"key":"2916_CR44","doi-asserted-by":"publisher","first-page":"100621","DOI":"10.1016\/j.curtheres.2020.100621","volume":"94","author":"G Dessie","year":"2021","unstructured":"Dessie G, Mulugeta H, Wagnew F, Zegeye A, Kiross D, Negesse A, et al. Immunological treatment failure among adult patients receiving highly active antiretroviral therapy in East africa: A systematic review and Meta-Analysis. Curr Ther Res Clin Exp. 2021;94:100621.","journal-title":"Curr Ther Res Clin Exp"},{"key":"2916_CR45","doi-asserted-by":"crossref","unstructured":"Ulrik Bak Dragsted AM, Stefano Vella J-P, Viard, Ann-Britt E, Hansen G, Panos D, Mercey L, Machala A, Horban, Jens D. Lundgren. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1\u2013Infected adults: A EuroSIDA study. The Journal of Infectious Diseases 2004.","DOI":"10.1086\/420786"},{"issue":"10","key":"2916_CR46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1473-3099(11)70141-4","volume":"11","author":"KC Sigaloff","year":"2011","unstructured":"Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TFR. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011;11(10):769\u201379.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2916_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4103\/0253-7184.85412","volume":"32","author":"B Prabhakar","year":"2011","unstructured":"Prabhakar B, Banu A, Pavithra HB, Chandrashekhara P, Sasthri S. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian J Sex Transm Dis AIDS. 2011;32(2):94\u20138.","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"2","key":"2916_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4314\/ahs.v23i2.12","volume":"23","author":"M Echchakery","year":"2023","unstructured":"Echchakery M, Boumezzough A, Boussaa S. Biological parameters determining the effectiveness of monitoring of HIV \/ AIDS infected patients in Morocco. Afr Health Sci. 2023;23(2):109\u201320.","journal-title":"Afr Health Sci"},{"issue":"11","key":"2916_CR49","doi-asserted-by":"publisher","first-page":"e006088","DOI":"10.1136\/bmjgh-2021-006088","volume":"6","author":"V Ameli","year":"2021","unstructured":"Ameli V, Taj L, Barlow J, Sabin L, Meinck F, Haberer J, et al. You just prefer to die early!\u2019: how socioecological context impedes treatment for people living with HIV in Iran. BMJ Global Health. 2021;6(11):e006088.","journal-title":"BMJ Global Health"},{"issue":"9","key":"2916_CR50","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"GA McComsey","year":"2021","unstructured":"McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-World adherence to antiretroviral therapy among HIV-1 patients across the united States. Adv Ther. 2021;38(9):4961\u201374.","journal-title":"Adv Ther"},{"issue":"1","key":"2916_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.14302\/issn.2324-7339.jcrhap-16-1316","volume":"3","author":"GS Liranso","year":"2017","unstructured":"Liranso GS, Mohan SS, Eyerus A. The psychosocial factors that influencing antiretroviral treatment adherence. J Clin Res HIV AIDS Prev. 2017;3(1):31\u20139.","journal-title":"J Clin Res HIV AIDS Prev"},{"issue":"3","key":"2916_CR52","doi-asserted-by":"publisher","first-page":"e0001007","DOI":"10.1371\/journal.pgph.0001007","volume":"3","author":"R Masaba","year":"2023","unstructured":"Masaba R, Woelk G, Siamba S, Ndimbii J, Ouma M, Khaoya J, et al. Antiretroviral treatment failure and associated factors among people living with HIV on therapy in homa bay, kenya: A retrospective study. PLOS Global Public Health. 2023;3(3):e0001007.","journal-title":"PLOS Global Public Health"},{"issue":"51","key":"2916_CR53","doi-asserted-by":"publisher","first-page":"e28357","DOI":"10.1097\/MD.0000000000028357","volume":"100","author":"J Siraj","year":"2021","unstructured":"Siraj J, Feyissa D, Mamo Y, Zewudie A, Regesa T, Ejeta F, et al. Antiretroviral treatment failure and associated factors among HIV patients on the first-line antiretroviral therapy at Mizan-Tepi university teaching hospital, Southwest ethiopia: A cross-sectional study. Med (Baltim). 2021;100(51):e28357.","journal-title":"Med (Baltim)"},{"issue":"6","key":"2916_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3851\/IMP3331","volume":"24","author":"V Vannappagari","year":"2019","unstructured":"Vannappagari V, Ragone L, Henegar C, van Wyk J, Brown D, Demarest J, et al. Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review. Antivir Ther. 2019;24(6):393\u2013404.","journal-title":"Antivir Ther"},{"issue":"8","key":"2916_CR55","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/v15081732","volume":"15","author":"FET Foka","year":"2023","unstructured":"Foka FET, Mufhandu HT. Current arts, virologic failure, and implications for AIDS management: a systematic review. Viruses. 2023;15(8):1732.","journal-title":"Viruses"},{"key":"2916_CR56","doi-asserted-by":"crossref","unstructured":"Shalaka NJEMHJ. Retrospective study of the prevalence of acquired drug resistance after failed antiretroviral therapy in Libya. 2024;30(7).","DOI":"10.26719\/2024.30.7.470"},{"key":"2916_CR57","unstructured":"Mazaheri Z, Tahaghoghi-Hajghorbani S, Baesi K, Ghazvini K, Amel-Jamehdar S, Youssefi MJMBRC. A survey of resistance mutations to reverse transcriptase inhibitors (RTIs) among HIV-1 patients in Northeast of Iran. 2024;13(3):117."},{"key":"2916_CR58","doi-asserted-by":"crossref","unstructured":"Wagner T, Levy I, Elbirt D, Shahar E, Olshtain-Pops K, Elinav H et al. Factors associated with virological failure in First-Line antiretroviral therapy in patients diagnosed with HIV-1 between 2010 and 2018 in Israel. 2023;15(12):2439.","DOI":"10.3390\/v15122439"},{"issue":"6","key":"2916_CR59","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.1542\/peds.2006-1232","volume":"119","author":"JM Simoni","year":"2007","unstructured":"Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119(6):e1371\u201383.","journal-title":"Pediatrics"},{"key":"2916_CR60","doi-asserted-by":"crossref","unstructured":"Madani N. Gender equality is crucial to the fight for better HIV treatment access and outcomes in the MENA region. Afr J Reprod Gynaecol Endoscopy. 2018;21(3).","DOI":"10.1002\/jia2.25092"},{"issue":"7","key":"2916_CR61","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1016\/S2352-3018(22)00129-1","volume":"9","author":"M Karamouzian","year":"2022","unstructured":"Karamouzian M, Sharifi H. Simulating HIV dynamics in the middle East and North Africa. Lancet HIV. 2022;9(7):e454\u20135.","journal-title":"Lancet HIV"},{"key":"2916_CR62","unstructured":"Moradi G, Ghaderi E, Sargolzaei M, Fallahi H, Eybpoosh S, Tayeri K et al. HIV\/AIDS surveillance system in the Islamic Republic of Iran: history, structures and processes. 2019."},{"key":"2916_CR63","doi-asserted-by":"crossref","unstructured":"Alinaghi SAS, Rasoolinejad M, Najafi Z, Dadras O, Malekianzadeh E. Mirzazadeh AJAocid. Drug resistance patterns in HIV patients with virologic failure in Iran. 2019;14(6):e96531.","DOI":"10.5812\/archcid.96531"},{"key":"2916_CR64","doi-asserted-by":"crossref","unstructured":"Yildiz Sevgi D, Gunduz A, Altuntas Aydin O, Mete B, Sargin F, Kumbasar Karaosmanoglu H et al. Adherence to antiretroviral therapy in turkey: results from the ACTHIV-IST study group. 2017;33(12):1192\u20138.","DOI":"10.1089\/aid.2016.0266"},{"key":"2916_CR65","doi-asserted-by":"crossref","unstructured":"Bokharaei-Salim F, Esghaei M, Khanaliha K, Kalantari S, Marjani A, Fakhim A et al. HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and Na\u00efve HIV-infected individuals. 2020;15(3):e0229275.","DOI":"10.1371\/journal.pone.0229275"},{"key":"2916_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-020-00328-6","volume":"18","author":"V Korten","year":"2021","unstructured":"Korten V, G\u00f6kengin D, Eren G, Y\u0131ld\u0131rmak T, Gencer S, Eraksoy H, et al. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR cohort, 2011\u20132017. AIDS Res Therapy. 2021;18:1\u201313.","journal-title":"AIDS Res Therapy"},{"issue":"4","key":"2916_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/labmed\/lmaa106","volume":"52","author":"T Hashempour","year":"2021","unstructured":"Hashempour T, Moayedi J, Mousavi Z, Esmaeli M, Asadzadeh A, Hasanshahi Z, et al. Incidence of hepatotoxicity in Iranian patients with HIV on antiretroviral therapies and its correlation with virologic response to HIV treatment. Lab Med. 2021;52(4):369\u201374.","journal-title":"Lab Med"},{"key":"2916_CR68","unstructured":"Rasooli-Nejad M, Khazaee-Pool M, Abbasian L, Jozani ZB, Ahsani-Nasab S, Badie BM et al. Assessing the efficacy of second-line antiretroviral treatment for Hiv patients failing first-line antiretroviral therapy in iran: a cohort study. Acta Medica Iranica. 2017:233\u201340."},{"key":"2916_CR69","doi-asserted-by":"crossref","unstructured":"Rasoolinejad M, Sarraf M, Najafi Z, Alinaghi SAS, Badie BM, Salehi M et al. Virologic failure in different antiretroviral regimens among pediatric patients with HIV referring to a voluntary counseling and testing (VCT) center in tehran, Iran (2004\u20132017). ARCHIVES OF PEDIATRIC INFECTIOUS DISEASES. 2019;7(4).","DOI":"10.5812\/pedinfect.80318"},{"issue":"5","key":"2916_CR70","doi-asserted-by":"publisher","first-page":"e0125826","DOI":"10.1371\/journal.pone.0125826","volume":"10","author":"KD Yirdaw","year":"2015","unstructured":"Yirdaw KD, Hattingh S. Prevalence and predictors of immunological failure among HIV patients on HAART in Southern Ethiopia. PLoS ONE. 2015;10(5):e0125826.","journal-title":"PLoS ONE"},{"key":"2916_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3339-7","volume":"18","author":"M Al-Mozaini","year":"2018","unstructured":"Al-Mozaini M, Alrahbeni T, Al-Mograbi R, Alrajhi A. Antiretroviral resistance in HIV-1 patients at a tertiary medical Institute in Saudi arabia: a retrospective study and analysis. BMC Infect Dis. 2018;18:1\u201310.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2916_CR72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00430-015-0419-9","volume":"204","author":"MO K\u00f6ksal","year":"2015","unstructured":"K\u00f6ksal MO, Beka H, L\u00fcbke N, Verheyen J, Eraksoy H, Cagatay A, et al. HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in istanbul, Turkey. Med Microbiol Immunol. 2015;204(4):551\u20135.","journal-title":"Med Microbiol Immunol"},{"issue":"8","key":"2916_CR73","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1089\/aid.2011.0278","volume":"28","author":"H El Annaz","year":"2012","unstructured":"El Annaz H, Recordon-Pinson P, Tagajdid R, Doblali T, Belefquih B, Oumakhir S, et al. Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. AIDS Res Hum Retroviruses. 2012;28(8):944\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2916_CR74","doi-asserted-by":"crossref","unstructured":"Siddiqui D, Badar U, Javaid M, Farooqui N, Shah SA, Iftikhar A et al. Genetic and antiretroviral drug resistance mutations analysis of reverse transcriptase and protease gene from Pakistani people living with HIV-1. 2023;18(8):e0290425.","DOI":"10.1371\/journal.pone.0290425"},{"issue":"9","key":"2916_CR75","first-page":"987","volume":"31","author":"GA Jamjoom","year":"2010","unstructured":"Jamjoom GA, Azhar EI, Madani TA, Hindawi SI, Bakhsh HA, Damanhouri GA. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia. Saudi Med J. 2010;31(9):987\u201392.","journal-title":"Saudi Med J"},{"issue":"6","key":"2916_CR76","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000497036","volume":"61","author":"M Mohraz","year":"2019","unstructured":"Mohraz M, Tayeri K, Tabar HN, Jozani ZB, Sadeghi L, SeyedAlinaghi S, et al. Evaluation of acquired HIV drug resistance among people living with HIV who have taken antiretroviral therapy for 9\u201315 months in 14 triangular clinics in iran, 2015\u20132016. Intervirology. 2019;61(6):292\u2013300.","journal-title":"Intervirology"},{"key":"2916_CR77","doi-asserted-by":"crossref","unstructured":"Ghasabi F, Hashempour A, Khodadad N, Bemani S, Keshani P, Shekiba MJ et al. First report of computational protein\u2013ligand Docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. Biochem Biophys Rep. 2022;30.","DOI":"10.1016\/j.bbrep.2022.101254"},{"issue":"6","key":"2916_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.5144\/0256-4947.2012.565","volume":"32","author":"SH Al Hajjar","year":"2012","unstructured":"Al Hajjar SH, Frayha H, Althawadi S. Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy. Ann Saudi Med. 2012;32(6):565\u20139.","journal-title":"Ann Saudi Med"},{"key":"2916_CR79","doi-asserted-by":"crossref","unstructured":"\u00c7ABALAK M, BAL T, POLAT ES, \u00d6NLEN OCAKS. Y. Examination of the reasons for change in treatment in patients infected with human immunodeficiency virus. 2023.","DOI":"10.4274\/mjima.galenos.2023.2022.2"},{"key":"2916_CR80","unstructured":"ZAEEM-UL-SAQIB, TL. Predictive markers of first line failure of Anti-Retroviral therapy in HIV positive patients in Pakistan."},{"key":"2916_CR81","doi-asserted-by":"crossref","unstructured":"Tebourski F, Jlizi A, Elgaaied A, Slim A, Garbouj MJJ. Difficulties encountered with antiretroviral treatment and genotypic testing of HIV-1 drug resistance in the developing countries: the Tunisian experience (North Africa). 2004;29(1):69.","DOI":"10.1016\/j.jcv.2003.09.001"},{"issue":"4","key":"2916_CR82","first-page":"538","volume":"23","author":"MR Jahani","year":"2009","unstructured":"Jahani MR, Kheirandish P, Hosseini M, Shirzad H, SeyedAlinaghi SA, Karami N, et al. HIV seroconversion among injection drug users in detention. Tehran Iran. 2009;23(4):538\u201340.","journal-title":"Tehran Iran"},{"key":"2916_CR83","unstructured":"Gholami M, Rouzbahani NH, Taj L, Tayeri K, Seyedalinaghi S, Manshadi SADJJITM. First report of drug resistance against HIV-1 integrase inhibitors in Iran. 2019;7(1):19\u201324."},{"key":"2916_CR84","doi-asserted-by":"crossref","unstructured":"Nasiri-Tajabadi Z, Bokharaei Salim F, Najafzadeh M-J, Kalantari S, Garshasbi S, Amel Jamehdar S et al. A surveillance on protease inhibitor resistance-associated mutations among Iranian hiv-1 patients. 2018;13(6):6.","DOI":"10.5812\/archcid.69153"},{"key":"2916_CR85","doi-asserted-by":"crossref","unstructured":"Shafiekhani M, Karimi S, ali Davarpanah M, Vazin AJH. Problems ARIJoH-R. Evaluating drug interactions, adverse drug reactions, and level of adherence to highly active antiretroviral therapy regimen amongst HIV-positive patients who referred to an AIDS healthcare center in fars, Southern iran: the first multifaceted study from Iran. 2017;16(1):24\u201331.","DOI":"10.5114\/hivar.2017.65334"},{"key":"2916_CR86","doi-asserted-by":"crossref","unstructured":"Fall-Malick FZ, Tchiakp\u00e9 E, Ould Soufiane SA, Diop\u2010Ndiaye H, Mouhamedoune Baye A, Ould Horma Babana A et al. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania. 2014;86(3):404\u201310.","DOI":"10.1002\/jmv.23860"},{"key":"2916_CR87","doi-asserted-by":"crossref","unstructured":"Elmi Abar A, Jlizi A, Darar HY, Kacem MABH, Slim, AJDp. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) Na\u00efve and first-line treatment failures in Djiboutian patients. 2012;7:1\u20137.","DOI":"10.1186\/1746-1596-7-138"},{"key":"2916_CR88","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00038-017-1023-0","volume":"63","author":"Trends in HIV\/AIDS morbidity and mortality in Eastern Mediterranean countries","year":"2018","unstructured":"Trends in HIV\/AIDS morbidity and mortality in Eastern Mediterranean countries. 1990\u20132015: findings from the global burden of disease 2015 study %J. Int J Public Health. 2018;63:123\u201336.","journal-title":"Int J Public Health"},{"issue":"3","key":"2916_CR89","first-page":"241","volume":"18","author":"L Sadeghi","year":"2018","unstructured":"Sadeghi L, Lolaie M, Tabatabai RA, Bayanolhagh S, Taj L, Ahmadi NE, et al. HIV-1 drug resistance profiles for the HIV protease and reverse transcriptase gene in patients receiving combination therapy in Tehran. Iran. 2018;18(3):241\u20138.","journal-title":"Iran"},{"issue":"1","key":"2916_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/011570162X273321240105081444","volume":"22","author":"F Bokharaei-Salim","year":"2024","unstructured":"Bokharaei-Salim F, Khanaliha K, Monavari SH, Kiani SJ, Tavakoli A, Jafari E, et al. Human immunodeficiency Virus-1 drug resistance mutations in Iranian Treatment-experienced individuals. Curr HIV Res. 2024;22(1):53\u201364.","journal-title":"Curr HIV Res"},{"key":"2916_CR91","doi-asserted-by":"crossref","unstructured":"Wagner T, Levy I, Elbirt D, Shahar E, Olshtain-Pops K, Elinav H et al. Factors associated with virological failure in First-Line antiretroviral therapy in patients diagnosed with HIV-1 between 2010 and 2018 in Israel. Viruses. 2023;15(12).","DOI":"10.3390\/v15122439"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02916-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:02:49Z","timestamp":1761609769000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2916"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02916-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review did not involve human subjects; therefore, ethics approval and patient consent were not applicable (Research proposal code: 29475; Ethics code: IR.SUMS.REC.1403.145).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"344"}}